Sagimet Biosciences Inc. (SGMT) · Sep 30, 2026 · Other events

Sagimet acne trial shows durable 52-week gains ahead of U.S. Phase 3

Above the bar — 57% IGA treatment success; 72% total-lesion and 77% inflammatory-lesion reductions

Sagimet’s acne trial adds durable 52-week efficacy and tolerability data, strengthening the case for its U.S. AURORA Phase 3 launch.

Sagimet is a clinical-stage biotech narrowing its strategy around denifanstat in acne: after securing FDA clearance to proceed, it is moving toward a U.S. registrational Phase 3 trial, while deprioritizing MASH unless it finds non-dilutive funding. That U.S. Phase 3 plan was already publicly telegraphed for the second half of 2026, and the company had said in August that screening was on track for the fourth quarter, so the direction of travel was known.

The new information is the durability, not the existence of efficacy. Sagimet’s partner had already reported positive topline open-label-extension data earlier in 2026; this filing supplies the full 52-week readout and confirms continued improvement after the original 12-week randomized study. The OLE included 240 patients, with efficacy assessed from the ASC40-303 baseline. 〔0〕

52-week OLE resultTotal cohortFiling reference
IGA treatment success56.7%(Phase 3 Open-Label Extension Results)
Total-lesion change from baseline-71.8%(Phase 3 Open-Label Extension Results)
Inflammatory-lesion change from baseline-76.9%(Phase 3 Open-Label Extension Results)
Non-inflammatory-lesion change from baseline-66.9%(Phase 3 Open-Label Extension Results)
Treatment-related dry skin7.1%(Phase 3 Open-Label Extension Results)
Treatment-related dry eye5.9%(Phase 3 Open-Label Extension Results)

The result clears the trial’s practical bar, but it is not a fresh placebo-controlled win. The open-label design and secondary efficacy endpoints make this primarily a long-term support package for the U.S. program, not a new controlled proof-of-concept event. Still, the magnitude of sustained lesion reduction and the similar response rates for prior placebo patients versus prior denifanstat patients strengthen the case that benefit can continue beyond 12 weeks. 〔1〕

Long-term tolerability remains supportive rather than decisive. Through 52 weeks, the filing reports no drug-related serious adverse events and no permanent discontinuations caused by adverse events; the main recurring treatment-related issues were dry skin and dry eye. 〔2〕 That reduces one important development concern, but the decisive test remains whether the U.S. randomized AURORA study reproduces the efficacy signal in a different population and trial setting.

The ATM termination is a secondary capital-market housekeeping item, not a new financing. Sagimet will not sell shares under the existing prospectus supplement unless it files a replacement prospectus or registration statement, so this removes near-term use of that issuance channel but does not change the separate sales agreement. 〔3〕

Bottom line: The filing upgrades denifanstat’s acne story from promising short-term efficacy to credible 52-week durability and tolerability. It matters because it supports the imminent U.S. Phase 3 launch, although the core clinical risk has shifted to reproducing these results in the controlled AURORA trial rather than proving that the drug can work long term in China’s open-label extension.

What to watch next

AURORA patient screening, October 2026

Original filing on SEC EDGAR

More Sagimet Biosciences Inc. news

Sagimet acne trial shows durable 52-week gains ahead of U.S. Phase 3 | SGMT Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.